Doxorubicin selectively induces apoptosis through the inhibition of a novel isoform of Bcl‑2 in acute myeloid leukaemia MOLM‑13 cells with reduced Beclin 1 expression

Vu,Milan; Kassouf,Nick; Ofili,Rosemary; Lund,Torben; Bell,Celia; Appiah,Sandra

doi:10.3892/ijo.2020.5052

Doxorubicin selectively induces apoptosis through the inhibition of a novel isoform of Bcl‑2 in acute myeloid leukaemia MOLM‑13 cells with reduced Beclin 1 expression

Authors:
- Milan Vu
- Nick Kassouf
- Rosemary Ofili
- Torben Lund
- Celia Bell
- Sandra Appiah
View Affiliations

Affiliations: Department of Natural Sciences, Faculty of Science and Technology, Middlesex University, London NW4 4BT, UK
Published online on: April 23, 2020 https://doi.org/10.3892/ijo.2020.5052
Pages: 113-121
Copyright: © Vu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The overexpression of anti‑apoptotic Bcl‑2 in acute myeloid leukaemia (AML) may contribute to difficulties in eradicating these cells during chemotherapy. In the present study, doxorubicin (Dox) was evaluated for its potential to induce selective apoptotic cell death in AML MOLM‑13 cells and to modulate autophagy through Bcl‑2 and Beclin 1 protein expression. Annexin V/propidium iodide and 5(6)‑carboxyfluorescein diacetate succinimidyl ester (CFSE) flow cytometric analyses were conducted to determine the effects of Dox on cell death and cell proliferation, respectively, following 48 h of co‑incubation with AML MOLM‑13 or U‑937 monocytic cells. The protein expression levels of Bcl‑2 and Beclin 1 in untreated and treated cells were quantified by western blot analysis. Dox reduced the viability of MOLM‑13 cells partly by inhibiting cell division and inducing cell apoptosis. Dox demonstrated a level of selectivity in its cytotoxicity against MOLM‑13 compared to U‑937 cells (P<0.05). Dox induced a significant decrease in Beclin 1 protein levels in MOLM‑13 cells without significantly affecting the protein levels in U‑937 monocytes. A novel Bcl‑2 15‑20 kDa (p15‑20‑Bcl‑2) isoform was found to be selectively expressed in AML MOLM‑13 cells (but absent in the leukaemic cell lines tested, OCI‑AML2, CML K562 and U‑937). Dox induced a highly significant inhibition of p15‑20‑Bcl‑2 at concentrations of 0.5, 0.75 and 1 µM (P<0.01). However, the usual 26 kDa Bcl‑2 (p26‑Bcl‑2‑α) isoform protein expression was not affected by the drug in either the MOLM‑13 or U‑937 cells. It was thus postulated that Dox exhibited some selectivity by targeting the p15‑20‑Bcl‑2 isoform in MOLM‑13 cells and activating Beclin 1 to induce cell death.

View Figures

View References

1	Cancer Research UK: Leukaemia (all subtypes combined) statistics. Cancer Research UK; Oxford: 2016, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia.
2	Lun Y, Yang JJ and Wu Y: Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy. J Clin Pharm Ther. 42:786–789. 2017. View Article : Google Scholar : PubMed/NCBI
3	Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringers CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, et al: Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 20:53–65. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hassan C, Afshinnekoo E, Li S, Wu S and Mason CE: Genetic and epigenetic heterogeneity and the impact on cancer relapse. Exp Hematol. 54:26–30. 2017. View Article : Google Scholar : PubMed/NCBI
5	Madanat YF, Kalaycio ME and Nazha A: Advances in acute myeloid leukemia genomics, where do we stand in 2018? Acta Med Acad. 48:35–44. 2019.PubMed/NCBI
6	Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, et al: Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 481:506–510. 2012. View Article : Google Scholar : PubMed/NCBI
7	Zahreddine H and Borden KLB: Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 4:282013. View Article : Google Scholar : PubMed/NCBI
8	Hu X and Xuan Y: Bypassing cancer drug resistance by activating multiple death pathways - a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett. 259:127–137. 2008. View Article : Google Scholar
9	Nikoletopoulou V, Markaki M, Palikaras K and Tavernarakis N: Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta. 1833:3448–3459. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B and Bao JK: Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
11	Radogna F, Dicato M and Diederich M: Cancer-type-specific crosstalk between autophagy, necroptosis and apoptosis as a pharmacological target. Biochem Pharmacol. 94:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
12	Goodall ML, Fitzwalter BE, Zahedi S, Wu M, Rodriguez D, Mulcahy-Levy JM, Green DR, Morgan M, Cramer SD and Thorburn A: The autophagy machinery controls cell death switching between apoptosis and necroptosis. Dev Cell. 37:337–349. 2016. View Article : Google Scholar : PubMed/NCBI
13	Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, et al: The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol. 9:218–224. 2007. View Article : Google Scholar : PubMed/NCBI
14	Ding WX, Ni HM, Gao W, Hou YF, Melan MA, Chen X, Stolz DB, Shao ZM and Yin XM: Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem. 282:4702–4710. 2007. View Article : Google Scholar
15	Decuypere JP, Parys JB and Bultynck G: Regulation of the autophagic bcl-2/beclin 1 interaction. Cells. 1:284–312. 2012. View Article : Google Scholar : PubMed/NCBI
16	Marquez RT and Xu L: Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res. 2:214–221. 2012.PubMed/NCBI
17	Lian J, Karnak D and Xu L: The Bcl-2-Beclin 1 interaction in (-)-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Autophagy. 6:1201–1203. 2010. View Article : Google Scholar : PubMed/NCBI
18	Usmani S, Sivagnanalingam U, Tkachenko O, Nunez L, Shand JC and Mullen CA: Support of acute lymphoblastic leukemia cells by nonmalignant bone marrow stromal cells. Oncol Lett. 17:5039–5049. 2019.PubMed/NCBI
19	Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, Katayama Y, Kimura G, Fujii N, Omoto E, Harada M, et al: Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia. 11:1469–1477. 1997. View Article : Google Scholar : PubMed/NCBI
20	Gomez-Bougie P, Maïga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez MS, Le Gouill S, Touzeau C, Moreau P, Pellat-Deceunynck C, et al: BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood. 132:2656–2669. 2018. View Article : Google Scholar : PubMed/NCBI
21	Campos EdV: Pinto R: Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia. Hematology Transfus Cell Ther. 41:169–177. 2019. View Article : Google Scholar
22	McHowat J, Swift LM, Arutunyan A and Sarvazyan N: Clinical concentrations of doxorubicin inhibit activity of myocardial membrane-associated, calcium-independent phospholipase A(2). Cancer Res. 61:4024–4029. 2001.PubMed/NCBI
23	Rudolfová P, Hanušová V, Skálová L, Bártíková H, Matoušková P and Boušová I: Effect of selected catechins on doxorubicin anti-proliferative efficacy and hepatotoxicity in vitro. Acta Pharm. 64:199–209. 2014. View Article : Google Scholar
24	Fornari FA, Randolph JK, Yalowich JC, Ritke MK and Gewirtz DA: Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 45:649–656. 1994.PubMed/NCBI
25	Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, Pietanza MC, et al: Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat Commun. 8:160782017. View Article : Google Scholar : PubMed/NCBI
26	Florou D, Patsis C, Ardavanis A and Scorilas A: Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells. Cancer Biol Ther. 14:587–596. 2013. View Article : Google Scholar : PubMed/NCBI
27	Panaretakis T, Pokrovskaja K, Shoshan MC and Grandér D: Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem. 277:44317–44326. 2002. View Article : Google Scholar : PubMed/NCBI
28	Gamen S, Anel A, Pérez-Galán P, Lasierra P, Johnson D, Piñeiro A and Naval J: Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res. 258:223–235. 2000. View Article : Google Scholar : PubMed/NCBI
29	Moon JH, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW and Kim DH: BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. Leuk Res. 34:166–172. 2010. View Article : Google Scholar
30	Bien S, Rimmbach C, Neumann H, Niessen J, Reimer E, Ritter CA, Rosskopf D, Cinatl J, Michaelis M, Schroeder HW, et al: Doxorubicin-induced cell death requires cathepsin B in HeLa cells. Biochem Pharmacol. 80:1466–1477. 2010. View Article : Google Scholar : PubMed/NCBI
31	Pilco-Ferreto N and Calaf GM: Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 49:753–762. 2016. View Article : Google Scholar : PubMed/NCBI
32	Akgul C, Moulding DA and Edwards SW: Alternative splicing of Bcl-2-related genes: Functional consequences and potential therapeutic applications. Cell Mol Life Sci. 61:2189–2199. 2004. View Article : Google Scholar : PubMed/NCBI
33	Guillem V, Amat P, Collado M, Cervantes F, Alvarez-Larrán A, Martínez J, Tormo E, Eroles P, Solano C and Hernández-Boluda JC: BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. Leuk Res. 39:1278–1284. 2015. View Article : Google Scholar
34	Tanaka S, Saito K and Reed JC: Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival. J Biol Chem. 268:10920–10926. 1993.PubMed/NCBI
35	Ghassemifar R, Forster L, Finlayson J, Calogero T, Augustson B, Joske D and Cull G: Differential expression of the Bcl-2 and Bax isoforms in CD19 positive B-lymphocytes isolated from patients diagnosed with chronic lymphocytic leukaemia. Pathology. 44:632–637. 2012. View Article : Google Scholar : PubMed/NCBI
36	Manetto V, Lorenzini R, Cordon-Cardo C, Krajewski S, Rosai J, Reed JC and Eusebi V: Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis. Virchows Arch. 430:125–130. 1997. View Article : Google Scholar : PubMed/NCBI
37	Huang JM, Lin TY, Chang D, Lin SL and Ying SY: Truncated Bcl-2, a potential pre-metastatic marker in prostate cancer. Biochem Biophys Res Commun. 306:912–917. 2003. View Article : Google Scholar : PubMed/NCBI
38	Messingerova L, Imrichova D, Kavcova H, Turakova K, Breier A and Sulova Z: Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates. Toxicol In Vitro. 29:1405–1415. 2015. View Article : Google Scholar : PubMed/NCBI
39	Daniel F, Legrand A, Pessayre D, Vadrot N, Descatoire V and Bernuau D: Partial Beclin 1 silencing aggravates doxorubicin- and Fas-induced apoptosis in HepG2 cells. World J Gastroenterol. 12:2895–2900. 2006. View Article : Google Scholar : PubMed/NCBI
40	Pan Y, Gao Y, Chen L, Gao G, Dong H, Yang Y, Dong B and Chen X: Targeting autophagy augments in vitro and in vivo anti-myeloma activity of DNA-damaging chemotherapy. Clin Cancer Res. 17:3248–3258. 2011. View Article : Google Scholar : PubMed/NCBI
41	Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD and Levine B: Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 122:927–939. 2005. View Article : Google Scholar : PubMed/NCBI
42	Boya P, González-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Métivier D, Meley D, Souquere S, Yoshimori T, et al: Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol. 25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
43	Smuder AJ, Kavazis AN, Min K and Powers SK: Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscle. J Appl Physiol (1985). 111:1190–1198. 2011. View Article : Google Scholar